Zimmer Biomet Holdings (ZBH)
NYSE:ZBH
Want to see ZBH full AI Analyst Report?
ZBH Stock Chart & Stats
$94.78
-$1.23(-1.19%)
At close: 4:00 PM EST
$94.78
-$1.23(-1.19%)
Day’s Range― - ―
52-Week Range$79.12 - $108.29
Previous CloseN/A
Volume487.31K
Average Volume (3M)2.68M
Market Cap
$16.20B
Enterprise Value$22.97B
Total Cash (Recent Filing)$424.20M
Total Debt (Recent Filing)$7.47B
Price to Earnings (P/E)21.8
Beta0.54
Next Earnings
Aug 04, 2026EPS Estimate
2.02Next Dividend Ex-DateN/A
Dividend Yield1.05%
Share Statistics
EPS (TTM)3.87
Shares Outstanding193,462,480
10 Day Avg. Volume2,376,802
30 Day Avg. Volume2,680,358
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue2.73
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda10.41
Forecast
1Y Price Target
$96.92Price Target Upside2.26% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)8.49
Revenue Forecast (FY)$8.55B
Bulls Say, Bears Say
Bulls Say
High Gross And EBITDA Margins From ScaleSustained high gross (~69.7%) and EBITDA (~26.9%) margins reflect durable manufacturing scale, premium product mix and operating leverage in implants and consumables. These margins provide long‑term funding for R&D, robotics rollout and margin cushions against moderate pricing pressure.
Consistent Cash Generation And FCF QualityFree cash flow exceeding net income and multi‑hundred million operating cash supports durable capital returns, M&A and investment in robotics/software. Strong cash conversion underpins balance sheet flexibility and cushions investment cycles despite near‑term FCF growth volatility.
Capital Allocation And Shareholder SupportElevated buyback capacity and shareholder votes for the board signal management discipline and continuity in capital allocation. This supports durable EPS accretion and signals confidence in cash generation while maintaining flexibility for strategic M&A and robotics commercialization investments.
Bears Say
Net Margin Compression And Falling ROEDeclining net margin and ROE indicate lower bottom‑line efficiency versus prior years despite stable gross margins. This suggests rising nonoperating costs, interest on acquisition debt or cost pressures that can structurally reduce returns on capital unless reversed by sustained margin or revenue improvements.
Sharp Negative FCF Growth And Cash VolatilityWhile absolute FCF is healthy, rapid negative FCF growth and weaker operating cash coverage point to working‑capital swings or one‑time timing effects. Structural volatility in cash generation can hamper predictable buybacks, debt paydown or funding for robotics rollouts over the medium term.
Commercial Transition, Pricing Erosion And Product HeadwindsOngoing salesforce restructuring, legacy knee phase‑outs and assumed price erosion are structural execution risks that can depress revenue mix and profitability over multiple quarters. Losses of large accounts and international go‑to‑market changes may slow durable share gains during transformation.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was $79.12 and its highest was $108.29 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is $16.20B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Aug 04, 2026 which is in 60 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Apr 28, 2026. The company reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.865 by $0.225.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of $0.24 which represents an annual dividend yield of 1.05%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 2.02.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 193,462,480 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of $2.09 in its last earnings report, beating expectations of $1.865. Following the earnings report the stock price went down -10.573%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$96.92 (2.26% Upside)
$96.92 (2.26% Upside)
Blogger Sentiment
Bullish
ZBH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 775.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $664.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.7%
Last 30 Days ▲ 14.6%
Last 30 Days ▲ 14.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.51%
12-Months-Change
Fundamentals
Return on Equity
5.78%
Trailing 12-Months
Asset Growth
2.42%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
ZBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented more positive developments than negative ones: solid top‑line growth (reported and organic), an EPS beat and raised EPS and free cash flow guidance, strong cash generation, accelerating performance from strategic acquisitions (Paragon 28) and clear momentum in technology and robotics (Monogram enrollment complete, ROSA/TMINI adoption). Offsetting items include short‑term disruption from the U.S. salesforce transformation and legacy knee transitions, some international go‑to‑market disruption, a one‑time tariff benefit that partially pulled forward upside, and higher interest expense tied to acquisition debt. On balance the company appears to be executing on its strategic priorities while managing expected transitional headwinds.View all ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical
ZBH Stock 12 Month Forecast
Average Price Target
$96.92
▲(2.26% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
46.80% Mutual Funds
13.80% Other Institutional Investors
11.32% Public Companies and
Individual Investors